The amount of the deal was not disclosed.
Using newly patented AI and platform technology, TeraRecon will continue to focus on expanding its open platform accelerating the use of AI in other clinical specialties, including neurology and oncology, in addition to its solutions in radiology, cardiology, and vascular surgery.
SymphonyAI Group will invest in infrastructure and key initiatives to produce new advancements and offerings through TeraRecon’s engineering and product teams. TeraRecon will operate as an independent portfolio company in the SymphonyAI Group. Synergies with TeraRecon technologies will complement the precision oncology offerings of portfolio company Concerto HealthAI.
Led by CEO Jeff Sorenson, who will be joined on the company’s board of directors by SymphonyAI Group CEO Romesh Wadhwani and partners Vibhor Rastogi, Leif Pedersen, and Pradyut Shah, TeraRecon provides medical advanced visualization and artificial intelligence solutions. Used by over 900 health systems globally, the solutions provide radiologists and other specialized physicians with the software tools they need to visualize and extract critical clinical data from medical images.
Led by Dr. Romesh Wadhwani, founder and CEO, SymphonyAI Group is a private group of B2B AI companies, which addresses use cases in healthcare and life sciences, retail and CPG, industrial manufacturing, energy, oil & gas, media and entertainment, defense, and financial services. Since its founding in 2017, the firm has grown to a group of seven companies with a combined revenue run rate of more than $300m.